These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 39403935)

  • 1. Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures.
    Kao CJ; Charmsaz S; Alden SL; Brancati M; Li HL; Balaji A; Munjal K; Howe K; Mitchell S; Leatherman J; Griffin E; Nakazawa M; Tsai HL; Danilova L; Thoburn C; Gizzi J; Gross NE; Hernandez A; Coyne EM; Shin SM; Babu JS; Apostol GW; Durham J; Christmas BJ; Konig MF; Lipson EJ; Naidoo J; Cappelli LC; Pabani A; Ged Y; Baretti M; Brahmer J; Hoffman-Censits J; Seiwert TY; Garonce-Hediger R; Guha A; Bansal S; Tang L; Jaffee EM; Chandler GS; Mohindra R; Ho WJ; Yarchoan M
    J Clin Invest; 2024 Aug; 134(20):. PubMed ID: 39403935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
    Tyan K; Baginska J; Brainard M; Giobbie-Hurder A; Severgnini M; Manos M; Haq R; Buchbinder EI; Ott PA; Hodi FS; Rahma OE
    Cancer Immunol Immunother; 2021 Aug; 70(8):2209-2221. PubMed ID: 33481042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center.
    Barlas T; Sutcuoglu O; Akdogan O; Balos Toruner F; Akturk M; Ozdemir N; Yazici O; Eroglu Altinova A
    Endocr Relat Cancer; 2024 Nov; 31(11):. PubMed ID: 39194584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
    van Eijs MJM; Verheijden RJ; van der Wees SA; Nierkens S; van Lindert ASR; Suijkerbuijk KPM; van Wijk F;
    Cancer Immunol Immunother; 2023 Dec; 72(12):4049-4064. PubMed ID: 37794264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
    Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events.
    Haugh AM; Daud AI
    J Clin Invest; 2024 Oct; 134(20):. PubMed ID: 39403930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Ju M; Zhang J; Deng Z; Wei M; Ma L; Chen T; Zhao L
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39089739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
    Alnemri AE; Tekumalla S; Moroco AE; Vathiotis I; Tuluc M; Gargano S; Zhan T; Cognetti DM; Curry JM; Argiris A; Linnenbach A; South AP; Harshyne LA; Johnson JM; Luginbuhl AJ
    Cancer Med; 2024 Jun; 13(11):e7370. PubMed ID: 38847087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
    JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.
    Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA
    Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M; Honda T; Hikita E; Masuo M; Miyazaki Y; Kobayashi M
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
    Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
    Assoumou L; Baldé R; Katlama C; Abbar B; Delobel P; Allegre T; Lavole A; Makinson A; Zaegel-Faucher O; Greillier L; Soulie C; Veyri M; Bertheau M; Algarte Genin M; Gibowski S; Marcelin AG; Bihan K; Baron M; Costagliola D; Lambotte O; Spano JP
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39179255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
    Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
    Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.